BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 16958828)

  • 1. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.
    Shams ME; Arneth B; Hiemke C; Dragicevic A; Müller MJ; Kaiser R; Lackner K; Härtter S
    J Clin Pharm Ther; 2006 Oct; 31(5):493-502. PubMed ID: 16958828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.
    Whyte EM; Romkes M; Mulsant BH; Kirshne MA; Begley AE; Reynolds CF; Pollock BG
    Int J Geriatr Psychiatry; 2006 Jun; 21(6):542-9. PubMed ID: 16642541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene.
    Arneth B; Shams M; Hiemke C; Härtter S
    Clin Biochem; 2009 Aug; 42(12):1282-90. PubMed ID: 19393232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood.
    Kingbäck M; Karlsson L; Zackrisson AL; Carlsson B; Josefsson M; Bengtsson F; Ahlner J; Kugelberg FC
    Forensic Sci Int; 2012 Jan; 214(1-3):124-34. PubMed ID: 21840145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.
    Kandasamy M; Srinivas P; Subramaniam K; Ravi S; John J; Shekar R; Srinivas N; Thangam S
    Eur J Clin Pharmacol; 2010 Sep; 66(9):879-87. PubMed ID: 20446083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time course of clinical response to venlafaxine: relevance of plasma level and chirality.
    Gex-Fabry M; Balant-Gorgia AE; Balant LP; Rudaz S; Veuthey JL; Bertschy G
    Eur J Clin Pharmacol; 2004 Feb; 59(12):883-91. PubMed ID: 14704834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder.
    Lobello KW; Preskorn SH; Guico-Pabia CJ; Jiang Q; Paul J; Nichols AI; Patroneva A; Ninan PT
    J Clin Psychiatry; 2010 Nov; 71(11):1482-7. PubMed ID: 20441720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability.
    Gex-Fabry M; Rudaz S; Balant-Gorgia AE; Brachet A; Veuthey JL; Balant LP; Bertschy G
    Eur J Clin Pharmacol; 2002 Aug; 58(5):323-31. PubMed ID: 12185556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
    Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
    J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine.
    Hynninen VV; Olkkola KT; Bertilsson L; Kurkinen K; Neuvonen PJ; Laine K
    Clin Pharmacol Ther; 2008 Feb; 83(2):342-8. PubMed ID: 17687273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversible cardiac dysfunction after venlafaxine overdose and possible influence of genotype and metabolism.
    Castanares-Zapatero D; Gillard N; Capron A; Haufroid V; Hantson P
    Forensic Sci Int; 2016 Sep; 266():e48-e51. PubMed ID: 27328779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.
    Fukuda T; Yamamoto I; Nishida Y; Zhou Q; Ohno M; Takada K; Azuma J
    Br J Clin Pharmacol; 1999 Apr; 47(4):450-3. PubMed ID: 10233212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report.
    Eap CB; Bertel-Laubscher R; Zullino D; Amey M; Baumann P
    Pharmacopsychiatry; 2000 May; 33(3):112-5. PubMed ID: 10855463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venlafaxine serum levels and CYP2D6 genotype.
    Veefkind AH; Haffmans PM; Hoencamp E
    Ther Drug Monit; 2000 Apr; 22(2):202-8. PubMed ID: 10774634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.
    Nichols AI; Lobello K; Guico-Pabia CJ; Paul J; Preskorn SH
    J Clin Psychopharmacol; 2009 Aug; 29(4):383-6. PubMed ID: 19593180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort.
    Kringen MK; Bråten LS; Haslemo T; Molden E
    J Clin Psychopharmacol; 2020; 40(2):137-144. PubMed ID: 32134850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine.
    McAlpine DE; Biernacka JM; Mrazek DA; O'Kane DJ; Stevens SR; Langman LJ; Courson VL; Bhagia J; Moyer TP
    Ther Drug Monit; 2011 Feb; 33(1):14-20. PubMed ID: 21099743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An observational study of Venlafaxine and CYP2D6 in clinical practice.
    Rolla R; Gramaglia C; Dalò V; Ressico F; Prosperini P; Vidali M; Meola S; Pollarolo P; Bellomo G; Torre E; Zeppegno P
    Clin Lab; 2014; 60(2):225-31. PubMed ID: 24660534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases.
    Karlsson L; Zackrisson AL; Josefsson M; Carlsson B; Green H; Kugelberg FC
    Pharmacogenomics J; 2015 Apr; 15(2):165-71. PubMed ID: 25245581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of CYP2D6 Genotypes on Venlafaxine Metabolism in Japanese Psychiatric Patients With Depression.
    Komahashi-Sasaki H; Yasui-Furukori N; Sasaki T; Shinozaki M; Hayashi Y; Kato K; Inoue Y; Tsuchimine S; Watanabe T; Sugawara N; Shimoda K
    Ther Drug Monit; 2021 Oct; 43(5):681-687. PubMed ID: 33306568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.